Progress in A Real-world Study of Abiraterone Acetate Versus Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer
10.3971/j.issn.1000-8578.2023.22.1152
- VernacularTitle:醋酸阿比特龙与多西他赛治疗转移性激素敏感性前列腺癌患者的真实世界研究进展
- Author:
Dongsheng MA
1
;
Hengqing AN
;
Yujie WANG
Author Information
1. Department of Urology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China
- Publication Type:Research Article
- Keywords:
Prostate cancer;
Abiraterone acetate;
Docetaxel;
Real-world study;
Drug evaluation
- From:
Cancer Research on Prevention and Treatment
2023;50(5):538-543
- CountryChina
- Language:Chinese
-
Abstract:
The safety and survival benefits of abiraterone acetate and docetaxel in the treatment of patients with metastatic hormone-sensitive prostate cancer have been confirmed by randomized controlled trials and clinical studies abroad. However, real-world studies remain lacking. In this article, we review the progress of real-world studies of abiraterone acetate and docetaxel in the treatment of patients with metastatic hormone-sensitive prostate cancer and the problems faced in clinical practice against the background of differentiated real-world studies. Further research is needed to address clinically important issues, such as individualized dosing, combination dosing, and monitoring of adverse effects.
